InvestSMART
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. Global X S&P Biotech ETF (CURE)
  6. Company Announcements

Global X S&P Biotech ETF (ASX: CURE) - Announcements

Current share price for CURE : $50.580 0.56 (1.12%)+

Global X S&P Biotech ETF (CURE) is an Exchange Traded Fund - commonly known as an ETF. For more details about how ETFs work, feel free to check out our What is an ETF? overview. The Global X S&P Biotech ETF (CURE) seeks to invest in companies that stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Latest company announcements for Global X S&P Biotech ETF (CURE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$37 Estimated Distribution Announcement - June 2022 24 Jun 2022 5:11PM $38.030 $50.580 risen by 33%
$37 Change of ownership and control of responsible entity 15 Jun 2022 12:21PM $31.680 $50.580 risen by 59.66%
$37 ETFS Units on Issue May 2022 3 Jun 2022 11:34AM $32.400 $50.580 risen by 56.11%
$37 Replacement PDS dated 9 May 2022 9 May 2022 8:49AM $35.680 $50.580 risen by 41.76%
$37 ETFS Units on Issue April 2022 2 May 2022 6:01PM $36.200 $50.580 risen by 39.72%
$37 ETFS Units on Issue March 2022 1 Apr 2022 4:15PM $41.350 $50.580 risen by 22.32%
$37 CURE Half Year Accounts 16 Mar 2022 8:51AM $38.990 $50.580 risen by 29.73%
$37 ETFS Units on Issue February 2022 1 Mar 2022 10:26AM $42.240 $50.580 risen by 19.74%
$37 ETFS Units on Issue January 2022 1 Feb 2022 5:01PM $45.580 $50.580 risen by 10.97%
$37 ETFS Units on Issue December 2021 5 Jan 2022 8:34AM $55.190 $50.580 fallen by 8.35%
$37 ETFS Units on Issue November 2021 1 Dec 2021 7:54PM $56.410 $50.580 fallen by 10.34%
$37 ETFS Units on Issue October 2021 2 Nov 2021 11:06AM $59.000 $50.580 fallen by 14.27%
$37 CURE Annual Financial Report 4 Oct 2021 11:37AM $59.560 $50.580 fallen by 15.08%
$37 ETFS Units on Issue September 2021 1 Oct 2021 8:27AM $59.920 $50.580 fallen by 15.59%
$37 ETFS Units on Issue August 2021 1 Sep 2021 12:45PM $62.580 $50.580 fallen by 19.18%
$37 ETFS Units on Issue Jul 2021 2 Aug 2021 12:27PM $57.900 $50.580 fallen by 12.64%
$37 ETFS Units on Issue Jun 2021 2 Jul 2021 8:19AM $62.420 $50.580 fallen by 18.97%
$37 Update - Dividend/Distribution - CURE 1 Jul 2021 7:13PM $62.420 $50.580 fallen by 18.97%
$37 Update - Dividend/Distribution - CURE 30 Jun 2021 9:06AM $68.920 $50.580 fallen by 26.61%
$37 Update - Dividend/Distribution - CURE 30 Jun 2021 8:19AM $68.920 $50.580 fallen by 26.61%
$37 Dividend/Distribution - CURE 24 Jun 2021 6:14PM $67.340 $50.580 fallen by 24.89%
$37 ETFS Units on Issue May 29021 1 Jun 2021 4:06PM $62.670 $50.580 fallen by 19.29%
$37 ETFS Units on Issue April 2021 7 May 2021 12:10PM $61.430 $50.580 fallen by 17.66%
$37 ETFS Units on Issue March 2021 1 Apr 2021 10:01AM $67.540 $50.580 fallen by 25.11%
$37 ETFS Units on Issue January 2021 2 Feb 2021 9:25AM $76.060 $50.580 fallen by 33.50%

51 - 75 of 97 results

Page 3 of 4

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.